Skip to content

European survey for endometrial cancer patients: Acute and long-term side-effect (Expression XXI)

European survey for endometrial cancer patients: Acute and long-term side-effect (Expression XXI) - NOGGO-S35 / ENGOT-en27 / SARA / Expression XXI

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00039077
Enrollment
500
Registered
2026-01-23
Start date
2026-02-16
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C54

Interventions

Group 1: Patients being treated for primary endometrial cancer (group A). All patients answer the same questionnaire, regardless of which arm they are in. Patients being treated for primary endometria

Sponsors

Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie e.V.
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of endometrial cancer

Exclusion criteria

Exclusion criteria: Patients with other tumors and patients under the age of 18.

Design outcomes

Primary

MeasureTime frame
Three patient groups will be compared: primary treatment, relapse treatment, and follow-up. The main objective is to assess the frequency of side effects, particularly polyneuropathy and hair loss.

Secondary

MeasureTime frame
- Assess treatment preferences - Evaluate decision-making for appropriate therapies - Assess patient adherence to recommended treatments - Analyse financial burden of the disease and its treatment - Analyse time burden associated with the disease and treatment - Evaluate access to healthcare and support systems - Assess patient education regarding the disease, genetic factors, and therapy options - Evaluate patients’ knowledge of medical guidelines - Analyse the impact of polyneuropathy and hair loss on overall quality of life across the three subgroups

Countries

France, Germany, United Kingdom

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026